000 02381 a2200661 4500
005 20250517063858.0
264 0 _c20160620
008 201606s 0 0 eng d
022 _a1097-0142
024 7 _a10.1002/cncr.29798
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchiff, David
245 0 0 _aPhase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
_h[electronic resource]
260 _bCancer
_cFeb 2016
300 _a582-7 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAlanine Transaminase
_xblood
650 0 4 _aAnilides
_xadministration & dosage
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xadministration & dosage
650 0 4 _aAspartate Aminotransferases
_xblood
650 0 4 _aAstrocytoma
_xpathology
650 0 4 _aBrain Neoplasms
_xpathology
650 0 4 _aChemoradiotherapy
_xmethods
650 0 4 _aChemoradiotherapy, Adjuvant
_xmethods
650 0 4 _aConstipation
_xchemically induced
650 0 4 _aDacarbazine
_xadministration & dosage
650 0 4 _aDiarrhea
650 0 4 _aFatigue
_xchemically induced
650 0 4 _aFemale
650 0 4 _aGlioblastoma
_xpathology
650 0 4 _aHumans
650 0 4 _aHypertension
_xchemically induced
650 0 4 _aL-Lactate Dehydrogenase
_xblood
650 0 4 _aLeukopenia
650 0 4 _aMaintenance Chemotherapy
_xmethods
650 0 4 _aMale
650 0 4 _aMaximum Tolerated Dose
650 0 4 _aMiddle Aged
650 0 4 _aNausea
_xchemically induced
650 0 4 _aNeoplasm Grading
650 0 4 _aNeurosurgical Procedures
650 0 4 _aNeutropenia
650 0 4 _aPyridines
_xadministration & dosage
650 0 4 _aTemozolomide
650 0 4 _aThrombocytopenia
_xchemically induced
650 0 4 _aTreatment Outcome
700 1 _aDesjardins, Annick
700 1 _aCloughesy, Timothy
700 1 _aMikkelsen, Thomas
700 1 _aGlantz, Michael
700 1 _aChamberlain, Marc C
700 1 _aReardon, David A
700 1 _aWen, Patrick Y
773 0 _tCancer
_gvol. 122
_gno. 4
_gp. 582-7
856 4 0 _uhttps://doi.org/10.1002/cncr.29798
_zAvailable from publisher's website
999 _c25467798
_d25467798